A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma.
- Resource Type
- Journal
- Source
MOLECULAR CANCER THERAPEUTICS ; DEC 2007, 6 12, p3385S-p3385S, 1p.- Subject
- Language
- English
- ISSN
- 15357163